Aptarion Biotech
Phase 2Aptarion Biotech develops new treatments for life-threatening diseases by leveraging the unique properties of mirror-image L-aptamers. Aptarion’s lead drug candidate AON-D21 is currently being tested in a Phase 2 clinical trial in 150 patients diagnosed with severe community-acquired pneumonia. The trial is running in five European countries and the USA (ADCAP trial).
Private Company
Total funding raised: $18.5M
About
Aptarion Biotech develops new treatments for life-threatening diseases by leveraging the unique properties of mirror-image L-aptamers. Aptarion’s lead drug candidate AON-D21 is currently being tested in a Phase 2 clinical trial in 150 patients diagnosed with severe community-acquired pneumonia. The trial is running in five European countries and the USA (ADCAP trial).